MEI PHARMA INC (MEIP) Stock Price & Overview
NASDAQ:MEIP • US55279B3015
Current stock price
The current stock price of MEIP is 3.07 USD. Today MEIP is up by 10.43%. In the past month the price decreased by -35.91%. In the past year, price increased by 1.32%.
MEIP Key Statistics
- Market Cap
- 100.819M
- P/E
- 1.15
- Fwd P/E
- N/A
- EPS (TTM)
- 2.67
- Dividend Yield
- N/A
MEIP Stock Performance
MEIP Stock Chart
MEIP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MEIP. When comparing the yearly performance of all stocks, MEIP is one of the better performing stocks in the market, outperforming 75.49% of all stocks.
MEIP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MEIP. No worries on liquidiy or solvency for MEIP as it has an excellent financial health rating, but there are worries on the profitability.
MEIP Earnings
MEIP Forecast & Estimates
6 analysts have analysed MEIP and the average price target is 6.12 USD. This implies a price increase of 99.35% is expected in the next year compared to the current price of 3.07.
For the next year, analysts expect an EPS growth of -339.91% and a revenue growth -100% for MEIP
MEIP Groups
Sector & Classification
MEIP Financial Highlights
Over the last trailing twelve months MEIP reported a non-GAAP Earnings per Share(EPS) of 2.67. The EPS increased by 157.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -152.38% | ||
| ROE | -162.03% | ||
| Debt/Equity | 0 |
MEIP Ownership
MEIP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.36 | 376.832B | ||
| AMGN | AMGEN INC | 15.29 | 188.135B | ||
| GILD | GILEAD SCIENCES INC | 15.42 | 169.255B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 112.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 79.215B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.36 | 41.92B | ||
| INSM | INSMED INC | N/A | 33.048B | ||
| BIIB | BIOGEN INC | 11.67 | 27.528B | ||
| NTRA | NATERA INC | N/A | 26.481B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.7 | 25.788B | ||
| MRNA | MODERNA INC | N/A | 19.048B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.372B | ||
| INCY | INCYTE CORP | 11.79 | 17.977B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MEIP
Company Profile
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2003-12-18. The firm's treasury initiative is anchored by Litecoin. The firm has discontinued the clinical development of voruciclib, while certain nonclinical activities related to its drug candidate assets continue to be conducted by it. As part of the review of strategic alternatives, the Company may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.
Company Info
IPO: 2003-12-18
MEI PHARMA INC
9920 Pacific Heights Blvd, Suite 150
San Diego CALIFORNIA 92130 US
CEO: Daniel P. Gold
Employees: 28
Phone: 18583697100
MEI PHARMA INC / MEIP FAQ
What does MEIP do?
MEI Pharma, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 28 full-time employees. The company went IPO on 2003-12-18. The firm's treasury initiative is anchored by Litecoin. The firm has discontinued the clinical development of voruciclib, while certain nonclinical activities related to its drug candidate assets continue to be conducted by it. As part of the review of strategic alternatives, the Company may consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities.
Can you provide the latest stock price for MEI PHARMA INC?
The current stock price of MEIP is 3.07 USD. The price increased by 10.43% in the last trading session.
Does MEIP stock pay dividends?
MEIP does not pay a dividend.
How is the ChartMill rating for MEI PHARMA INC?
MEIP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for MEIP stock?
6 analysts have analysed MEIP and the average price target is 6.12 USD. This implies a price increase of 99.35% is expected in the next year compared to the current price of 3.07.
What is the employee count for MEIP stock?
MEI PHARMA INC (MEIP) currently has 28 employees.
Can you provide the market cap for MEI PHARMA INC?
MEI PHARMA INC (MEIP) has a market capitalization of 100.82M USD. This makes MEIP a Micro Cap stock.